## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.2% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($247.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Community Health Systems offloads ambulatory business to Labcorp for $194M**
- Source: The Business Journals | 20251203T215214 | Somewhat-Bullish | Relevance: 100%
- Community Health Systems has completed the sale of some of its ambulatory assets to Labcorp for $194 million. This article briefly explains what assets were sold and how this transaction fits into the company's broader strategy.

**2. Labcorp (LH) director reports grant of 136 Restricted Stock Units vesting Dec. 2026**
- Source: Stock Titan | 20251203T133500 | Neutral | Relevance: 100%
- Labcorp Holdings Inc. director Victor Bulto Carulla reported the grant of 136 Restricted Stock Units (RSUs) on December 1, 2025. These RSUs represent the right to receive one share of Labcorp common stock each and are scheduled to vest fully on December 1, 2026. This transaction is a routine disclosure of director equity compensation and not an open-market purchase or sale.

**3. CHS sells lab assets to Labcorp for $194M**
- Source: Yahoo Finance | 20251204T021700 | Bullish | Relevance: 100%
- Community Health Systems (CHS) has divested some of its ambulatory outpatient laboratory services to Labcorp for approximately $194 million in cash. This strategic move allows CHS to concentrate on its core offerings, while Labcorp expands its services by gaining patient service centers and in-office phlebotomy locations across 13 states. The deal, initially announced in July, is expected to enhance patient access to Labcorpâ€™s specialized services.

**4. Is It Too Late To Consider Labcorp After Its Strong Multi Year Share Price Rally?**
- Source: Simply Wall Street | 20251203T155040 | Bullish | Relevance: 100%
- This article evaluates Labcorp Holdings (NYSE:LH) to determine if its stock, currently around $265, is still a worthwhile investment following a significant multi-year rally. The analysis uses Discounted Cash Flow (DCF) and Price-to-Earnings (PE) ratios, concluding that Labcorp appears undervalued by both metrics, suggesting a potential favorable entry point for long-term investors. It also introduces "Narratives" as a way for investors to create explicit fair value estimates based on their own forecasts.

**5. Price Over Earnings Overview: Labcorp Hldgs**
- Source: Benzinga | 20251203T150000 | Neutral | Relevance: 100%
- This article provides an overview of Labcorp Hldgs' (NYSE: LH) Price-to-Earnings (P/E) ratio. It details the current stock price and its performance over the last month and year, comparing Labcorp's P/E to the industry average to determine potential undervaluation or overvaluation. The article emphasizes that while the P/E ratio is a useful metric, it has limitations and should be used with other financial and qualitative analyses.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-07 | JP Morgan | $317 | $291 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-07 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 14.7x stretched relative to 7% growth. Analyst sentiment positive (1 raises, avg +9%). Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.1B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 14.7 |
| Current P/E | 15.8 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.3% to -4.2% (-5.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.00x) but short-term weakness (below SMA20). RSI neutral at 41. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.25% (CS: 16) | Weak |
| RSI_14 | 40.8 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 0.958x | Below |
| vs SMA200 | 1.005x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $258.39
- **Stop Loss:** $247.15 (4.4% risk)
- **Target:** $269.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 44
- **Position Value:** $11,369.16
- **Portfolio %:** 11.37%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*